DBV712 for Peanut Allergy
(EPOPEX Trial)

Recruiting in Palo Alto (17 mi)

+25 other locations

Age: < 18

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: DBV Technologies

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Open-label, follow-up study for subjects who completed the EPITOPE study.

Eligibility Criteria

This trial is for young children who have completed the EPITOPE study and are dealing with peanut allergies. It's not open to those who've developed severe, unstable asthma or have widespread skin conditions like active eczema that would prevent applying Viaskin patches on clear skin areas.

Inclusion Criteria

You have previously participated in the EPITOPE study.

Exclusion Criteria

I have widespread skin conditions like severe eczema, making it impossible to apply patches on my back or arms.

My asthma has become severe and hard to control.

Treatment Details

Interventions

DBV712 (Other)

Trial OverviewThe trial is testing the long-term efficacy and safety of a treatment called DBV712 at a dose of 250 mcg. This is an open-label follow-up study, meaning everyone knows they're getting the treatment and it's a continuation from an earlier phase.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: DBV712 250mcgExperimental Treatment1 Intervention